AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03207451
Drug: Vorapaxar
RxNorm normalized name: Vorapaxar
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vorapaxar is the principle study drug and will be given to all subjects.
Trial: NCT03207451
Drug: Vorapaxar and Aspirin
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
Trial: NCT03207451
Drug: Vorapaxar and Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
Trial: NCT03207451
Drug: Vorapaxar, Aspirin, and Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
Trial: NCT03552705
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
Trial: NCT01064271
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone Tablets 1 mg
Trial: NCT01149655
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Trial: NCT01149655
Drug: Aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
Trial: NCT03308669
Drug: Lasmiditan
RxNorm normalized name: lasmiditan
DrugBank: Lasmiditan (DB11732)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT03308669
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT00296751
Drug: Intravenous meperidine injection
RxNorm normalized name: meperidine Injection
DrugBank: Meperidine (DB00454)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00296751
Drug: Epidural Bupivacaine and fentanyl injection
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04288219
Drug: Nifedipine
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine 30mg, Pharmacotherapy
Trial: NCT01366664
Drug: Treatment sequence 2
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment Period 1 (stable dose of terazosin \[2, 5, or 10 mg\] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin \[2, 5, or 10 mg\] + dapoxetine 60 mg administered orally once daily for 5 days)
Trial: NCT04594759
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will be getting isotretinoin (1-1.5 mg/kg/week)
Trial: NCT00311363
Drug: GEn (XP13512)
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
Trial: NCT00311363
Drug: GEn (XP13512)
RxNorm normalized name: GEN-001
DrugBank: GEN-001 (DB17518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
Trial: NCT00396084
Drug: Gatifloxacin
RxNorm normalized name: Gatifloxacin
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400 mg/day x 7 days.
Trial: NCT00396084
Drug: Isoniazid
RxNorm normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isoniazid 300 mg/day x 7 days.
Trial: NCT00396084
Drug: Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 1000 mg/day x 7 days.
Trial: NCT00396084
Drug: Linezolid
RxNorm normalized name: Linezolid
DrugBank: Linezolid (DB00601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
Trial: NCT00396084
Drug: Moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg/day x 7 days.
Trial: NCT02885324
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive Cabozantinib
Trial: NCT04365023
Drug: platinum chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First line platinum chemotherapy
Trial: NCT01470001
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patient will receive solifenacin 5mg daily or placebo daily
Trial: NCT02974933
Drug: Apatinib combined with pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
Trial: NCT00492518
Drug: Acetylcysteine
RxNorm normalized name: Acetylcysteine
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03981536
Drug: AP-101
RxNorm normalized name: AP-101
DrugBank: AP-101 (DB17947)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by intravenous infusion (IV)
Trial: NCT04601740
Drug: Oral Semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with commercially available oral semaglutide according to local label and to routine clinical practice at the discretion of the treating physician. The decision to initiate treatment with commercially available oral semaglutide has been made by the patient/Legally Acceptable Representative (LAR) and the treating physician based on local label before and independently from the decision to include the patient in this study.
Trial: NCT00486005
Drug: Olanzapine Hydrochloride
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00486005
Drug: Nizatidine
RxNorm normalized name: Nizatidine
DrugBank: Nizatidine (DB00585)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02904759
Drug: Desmopressin
RxNorm normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02620813
Drug: Isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take isotretinoin as prescribed by their dermatologist.
Trial: NCT01806116
Drug: decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00103558
Drug: Lumiliximab with FCR
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Lumiliximab (DB06162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose, schedule, and duration specified in protocol
Trial: NCT01140971
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
Trial: NCT00863915
Drug: Ramipril10 mg Capsules, single dose
DrugBank: Ramipril (DB00178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
Trial: NCT04355364
Drug: Dornase Alfa Inhalation Solution [Pulmozyme]
RxNorm normalized name: dornase alfa Inhalation Solution [Pulmozyme]
DrugBank: Dornase alfa (DB00003)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by nebulization, at a dose of 2500 IU twice daily, 12 hours apart, for 7 consecutive days
Trial: NCT02564367
Drug: S-1
RxNorm normalized name: LIS-1
DrugBank: Tegafur (DB09256)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 18 cycles S-1, orally administered twice daily D1-14, q 3 wks~S-1 starting dose: 2 x 30 mg/m\^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m\^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m\^2 BSA, D1-14, q 3 wks
Trial: NCT03442725
Drug: Telotristat etiprate
RxNorm normalized name: Telotristat etiprate
DrugBank: Telotristat (DB14218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Trial: NCT03638128
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Solution for injection
Trial: NCT03638128
Drug: Alternative osteoporosis medications
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative osteoporosis medication/s at the discretion of the investigator.
Trial: NCT01856738
Drug: Rivastigmine
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule. Dose 3,0 - 6,0 mg BID
Trial: NCT05108766
Drug: Tildrakizumab 100 mg
RxNorm normalized name: tildrakizumab 100 mg/mL subcutaneous solution
DrugBank: Tildrakizumab (DB14004)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.
Trial: NCT00944918
Drug: fulvestrant
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
Trial: NCT00944918
Drug: anastrozole
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, once daily until disease progression.
Trial: NCT02672722
Drug: Definity
RxNorm normalized name: Definity
DrugBank: Perflutren (DB00556)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
Trial: NCT03316521
Drug: AMY-101
RxNorm normalized name: AMY-101
DrugBank: AMY-101 (DB14803)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
Trial: NCT00944918
Drug: exemestane
RxNorm normalized name: Exemestane
DrugBank: Exemestane (DB00990)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet, oral, once daily until disease progression.
Trial: NCT02743975
Drug: Bevacizumab-800CW
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dose finding: 4.5mg; 10mg; 25mg; 50mg
Trial: NCT03038516
Drug: Cholecalciferol
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
Trial: NCT00151333
Drug: SRA-333
RxNorm normalized name: SRA-737
DrugBank: SRA-737 (DB16876)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01535677
Drug: Dapagliflozin + Glucophage tablet fasted
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
Trial: NCT01535677
Drug: Dapagliflozin/metformin IR FDC tablet fasted
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
Trial: NCT01535677
Drug: Dapagliflozin + Glucophage tablet fed
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
Trial: NCT01535677
Drug: Dapagliflozin/metformin IR FDC tablet fed
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
Trial: NCT00680329
Drug: Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop in study eye(s) once daily in the evening for four months
Trial: NCT03339583
Drug: Zopiclone
RxNorm normalized name: zopiclone
DrugBank: Zopiclone (DB01198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: zopiclone intake in a dose of 7,5 mg 30 minutes before bedtime for two weeks
Trial: NCT00699049
Drug: solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02934256
Drug: Icotinib
RxNorm normalized name: icotinib
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
Trial: NCT03347097
Drug: TIL
RxNorm normalized name: Tilia
DrugBank: Tilia americana pollen (DB10732)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03347097
Drug: PD1-TIL
RxNorm normalized name: CD8 enriched young TIL
DrugBank: CD8+ enriched young tumor infiltrating lymphocytes (DB17460)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00234845
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03519906
Drug: Metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients are tested for their normal prescription metaprolol medication
Trial: NCT03591861
Drug: BCNU
RxNorm normalized name: BCNU
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: -Standard of care
Trial: NCT00335647
Drug: fluphenazine hydrochloride
RxNorm normalized name: Fluphenazine Hydrochloride
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02757040
Drug: Ibrutinib combined with As2O3
RxNorm normalized name: Ibrutinib
DrugBank: Rutin (DB01698)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: arsenic trioxide combined with ibrutinib in CLL
Trial: NCT02757040
Drug: ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: ibrutinib
Trial: NCT00958503
Drug: Thiamphenicol
RxNorm normalized name: thiamphenicol
DrugBank: Thiamphenicol (DB08621)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 and 1500 mg/day;tablets
Trial: NCT01353859
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 8 mg/kg iv every 4 weeks for a total of 6 infusions
Trial: NCT03909529
Drug: Digoxin 250 MCG Oral Tablet
RxNorm normalized name: digoxin 250 MCG Oral Tablet
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention is for study of drug drug interaction of digoxin when administered with spironolactone oral suspension
Trial: NCT02233218
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02233218
Drug: Amlodipine
RxNorm normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04545801
Drug: 0.25 mg/kg of Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients will recieve 0.25mg/kg of ketamine intravenously 5 min after spinal anesthesia
Trial: NCT01631227
Drug: Eprosartan
RxNorm normalized name: Eprosartan
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eprosartan 450 mg
Trial: NCT01631227
Drug: Eprosartan Mesylate
RxNorm normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eprosartan mesylate 600 mg
Trial: NCT01631227
Drug: Placebo Eprosartan mesylate
RxNorm normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo Eprosartan mesylate
Trial: NCT01242826
Drug: biphasic insulin aspart 50
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
Trial: NCT01680458
Drug: Fluconazole
RxNorm normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.~Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.~Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.~Absolute doses exceeding 600 mg/day are not recommended.
Trial: NCT04545801
Drug: 20ml of normal saline solution
RxNorm normalized name: NS-2
DrugBank: Reproxalap (DB16688)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20ml of normal saline solution intravenously 5 minutes after spinal anesthesia
Trial: NCT04193436
Drug: PF-06835919 25 mg
RxNorm normalized name: timolol
DrugBank: PF-06835919 (DB19163)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: PF-06835919 in 25 mg oral tablet will be administered on Day 1
Trial: NCT00036764
Drug: ixabepilone
RxNorm normalized name: Ixabepilone
DrugBank: Ixabepilone (DB04845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00327340
Drug: custirsen (OGX-011)/mitoxantrone
DrugBank: Mitoxantrone (DB01204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.~Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.~Patients could receive a maximum of 9 cycles of treatment.
Trial: NCT00327340
Drug: custirsen (OGX-011)/docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.~Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.~Patients could receive a maximum of 9 cycles of treatment.
Trial: NCT01325350
Drug: bimatoprost Formulation A
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Trial: NCT01325350
Drug: bimatoprost Formulation B
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Trial: NCT01325350
Drug: bimatoprost Formulation C
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Trial: NCT01325350
Drug: bimatoprost vehicle solution
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
Trial: NCT01325350
Drug: minoxidil 2% solution
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
Trial: NCT00700427
Drug: atomoxetine hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral 40-100 mg/day
Trial: NCT00171717
Drug: Cyclosporine - cyclosporine microemulsion
RxNorm normalized name: cyclosporine microemulsion
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02172144
Drug: BI 1744 CL solution for inhalation
RxNorm normalized name: hydroxypropyl bis-hydroxyethyldimonium chloride
DrugBank: Propyl acetate (DB01670)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00405366
Drug: sorafenib tosylate
RxNorm normalized name: Sorafenib Tosylate
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy